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AngiogenesisCardiacmuscle is unique because it contracts ceaselessly throughout the life and is highly resistant to fatigue. The
marvelous nature of the cardiac muscle is attributed to its matrix that maintains structural and functional integ-
rity and provides ambient micro-environment required for mechanical, cellular and molecular activities in the
heart. Cardiac matrix dictates the endothelium myocyte (EM) coupling and contractility of cardiomyocytes.
The matrix metalloproteinases (MMPs) and their tissue inhibitor of metalloproteinases (TIMPs) regulate matrix
degradation that determines cardiacﬁbrosis andmyocardial performance.Wehave shown thatMMP-9 regulates
differential expression of micro RNAs (miRNAs), calcium cycling and contractility of cardiomyocytes. The differ-
ential expression of miRNAs is associated with angiogenesis, hypertrophy and ﬁbrosis in the heart. MMP-9,
which is involved in the degradation of cardiac matrix and induction of ﬁbrosis, is also implicated in inhibition
of survival and differentiation of cardiac stem cells (CSC). Cardiacmatrix is distinct because it rendersmechanical
properties and provides a framework essential for differentiation of cardiac progenitor cells (CPC) into speciﬁc
lineage. Cardiac matrix regulates myocyte contractility by EM coupling and calcium transients and also directs
miRNAs required for precise regulation of continuous and synchronized beating of cardiomyocytes that is
indispensible for survival. Alteration in the matrix homeostasis due to induction of MMPs, altered expression
of speciﬁc miRNAs or impaired signaling for contractility of cardiomyocytes leads to catastrophic effects. This re-
view describes the mechanisms by which cardiac matrix regulates myocardial performance and suggests future
directions for the development of treatment strategies in cardiovascular diseases.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Although heart is a unique and dynamic organ functioning ceaselessly
throughout life, it is highly vulnerable to disease pathology. Cardiovascu-
lar disease (CVD) is the leading cause of morbidity and mortality across
the world. Although majority of research emphasize on CVD, less atten-
tion has been paid to the sophisticated regulatory mechanisms and
micro-environment provided by cardiac matrix. Cardiac matrix is crucial
for synchronized beating of cardiomyocytes that maintain the untiring
contraction relaxation cycle of the heart. Recently, it was discovered
that elasticity of matrix plays a pivotal role in lineage speciﬁcation [1]
and self-renewal [2] of stem cells. The heart has self-renewing capacity
due to endogenous cardiac stem cells [3]. It was reported that during
cardiac stem cell therapy, paracrine effect causing inhibition of cardiac
ﬁbrosis, apoptosis and enhanced contractility [4], could be a possible
factor mediated by matrix modulation. Another report using a cocktailiac stem cell; CPC, cardiac pro-
oteinase; TIMP, tissue inhibitor
ase; ECM, extracellular matrix;
romboembolism; DNMT, DNA
tor
).
ights reserved.of prosurvival miRNA-21, -24 and -221 was shown to enhance the
engraftment and viability of transplanted cardiac progenitor cells [5]
corroborating the fact that synergism of miRNA and stem cell could be
a better therapeutic approach in heart failure [6]. We have demon-
strated that targeted deletion of MMP-9 induces miRNAs that are
downregulated in failing hearts and improves contractility and calci-
um handling by up regulating SERCA2 in cardiomyocytes [7]. Addi-
tionally, induction of MMP-9 and attenuation of TIMP-4 contribute
to cardiac ﬁbrosis in diabetic hearts whereas ablation of MMP-9 de-
creases cardiac ﬁbrosis and increases cardiac stem cells (CPCs) in the
heart [8,9]. However, the cross-talk between MMP-9, miRNA and stem
cells is unclear. The understanding of complex interactions amongst
MMPs, miRNA and CPC in the milieu of cardiac matrix can be exploited
for regeneration and improvement of myocardial contractility. In this
review, the plausible mechanism of structural and functional remodel-
ing of cardiacmatrix in the context of heart failure and future therapeu-
tic approaches is elaborated.
2. Matrix metalloproteinases as key players in cardiac
matrix remodeling
MMPs are zinc containing calcium-dependent endopeptidases which
are released as inactive zymogens in a latent form [10,11] and are activat-
ed by auto-proteolysis, serine proteases, or other activated MMPs [10].
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sion) or volume overload, hyperhomocysteinemia, and/or activation of
renin angiotensin aldosterone system mediated oxidative/redox stress
that alters the levels of different MMPs and TIMPs and signaling mole-
cules leading to heart failure (Fig. 1). Cardiac remodeling includes degra-
dation of extracellular matrix (ECM), myocyte hypertrophy, impaired
angiogenesis, collateralization, changes in receptor signaling cascade,
ﬁbrosis, autophagy, apoptosis, impaired differentiation and survival of
CSC, fetal gene reprogramming, differential expressions of miRNAs and
epigenetic modiﬁcations. Although MMPs are involved in cardiovascular
remodeling, they have a distinct spatial and temporal role. The temporal
activation of MMP and TIMP has been elucidated in myocardial infarc-
tion. While MMP-2 induction was observed on day 1 and peaked at
two weeks post-MI, TIMP-4 induction and activation remained the
same from day 1 [12]. Similarly, MMP-9 but not MMP-2 was activated
in end-stage heart failure [13]. The spatial translocation of MMP-9
into mitochondria is associated with arrhythmia and cardiomyocyte
contractility dysfunction [14,15]. MMP-2 is constitutively expressed
[16–18], whereasMMP-9 is inducible and instigates pathophysiological
remodeling [7,9,19]. Although transgenic expression of MMP-2 impairs
myocardial contractility [20], the disruption of myocardial ﬁlament by
MMP-2 may not be true. The induction of MMP-2 may have an effect
on other MMPs. For example in diabetics, MMP-2 is attenuated but
MMP-9 shows robust activation [9] resulting in contractile dysfunction
[7]. MMP-2 is reported to be up regulated in human aortic atheroscle-
rotic lesions [21]. In heart failure, the level of MMP-2 increases during
compensatory stage but during de-compensatory stage MMP-9 super-
sedes the levels of MMP-2 resulting in failure [16]. Recently, the exis-
tence of a novel intracellular MMP-2 isoform was reported in the
mitochondria. This isoform is (65 kDA) induced by oxidative stress
and has been shown to play an important role in promoting cardiac hy-
pertrophy, apoptosis and systolic failure [22]. Despite the pathological
role described above, further studies are required to conﬁrm these ﬁnd-
ings. The vascular MMP versus cardiac MMP is interesting in the sense
that the remodeling outcome may be compensatory in cardiac matrix
while it is detrimental in the arterial pathology. Accumulation of colla-
gen and loss of elastin in the arterial wall correlate with decreased arte-
rial compliance in hypertension and aging. Enhanced extracellular
matrix remodeling in the arterial wall affects the course of disease pa-
thology in atherosclerosis [23]. Plaque disruption due to vascular re-
modeling mostly results in thrombotic occlusion [24].Fig. 1. Pressure and/volume overload, diabetes, homocysteine and renin angiotensin
aldosterone system (RAAS) engendered oxidative stress that activates latent MMPs and im-
balances MMP/TIMP axis (remodeling). This generates angiogenic and anti-angiogenic fac-
tors, leading to compensatory to de-compensatory congestive heart failure (CHF).MMPs are inhibited by tissue inhibitor of metalloproteinases (TIMPs).
There are four types of TIMPs: TIMP-1, -2, -3 and -4. TIMPs are implicated
in cardiac ﬁbrosis [25], angiogenesis [26,27], and apoptosis [28,29]. Cardi-
ac enriched TIMP-4 plays an important role inmatrix remodeling by inhi-
bition of MMP-9 activity [30]. An imbalance of MMP/TIMP has been
implicated in structural and functional changes in hypertensive heart dis-
ease [31]. The pathological role of MMPs in left ventricular remodeling
and heart failure has been extensively reported in both pre-clinical and
clinical studies [32]. In spontaneously hypertensive rats, MMP inhibition
was shown to attenuate pathological cardiac remodeling during hyper-
tension [33]. In a recent study, MMP-2 activity was found to be responsi-
ble for the development of left ventricular hypertrophy in a two kidney,
one clip hypertensive rat model [34]. In the same model, temporal
changes in MMP-2 activity was associated with simultaneous cardiac re-
modeling along with increased expression of TGF-β and reactive oxygen
species (ROS) [35]. Treatment with antioxidant, Tempol alleviated the
cardiac remodeling by decreasing the TGF-β and MMP expression [35].
Although signiﬁcant role of MMP-2 in remodeling has been extensively
reported, recent report suggests that the infusion of recombinant
human MMP-2 in lambs did not alter any hemodynamic parameters
but for the impairment of beta adrenoceptor activation response
[36].
The involvement of MMPs in left ventricular pathology has been ex-
tensively reported [37] however, a recent study in acute pulmonary
thromboembolism (APT) showed a similar role in right ventricular re-
modeling [38]. In APT, ROSproductionwas associatedwithMMP activa-
tion and treatment with non-speciﬁc MMP inhibitors or antioxidants
were found to mitigate MMP induced remodeling [39,40].
2.1. MMP inhibitors
MMP inhibitors are classiﬁed as speciﬁc and non-speciﬁc inhibi-
tors. Non-speciﬁc inhibitors act through chelation of Zn2+ ion [41].
Nonspeciﬁc inhibitors such as batimastat, marimastat, GM-6001
(ilomastat or gelardin), PD-166793 and ONO-4817 [42] have been ex-
tensively used in various experimentalmodels of disease. Lately, though
peptides containing the HWGFmotif, CRRHWGFEFC and CTTHWGFTLC,
were found to be selective inhibitors of MMP-9 and MMP-2 [41], their
clinical usage is highly questionable because of their susceptibility to
proteolysis inside the body. Tetracyclines are a group of antibiotics
that are found to have MMP inhibition property. Chemically modiﬁed
tetracyclines (CMTs) are devoid of antimicrobial property but retain
the MMP inhibition function [43]. CMT 3 has been shown to inhibit
MMP-2 and -9 activities along with collagenase activity and ameliorate
pathological cardiovascular remodeling. This is the only CMT adminis-
tered to humans in clinical trials [44].
3. Cross-talk between MMPs and miRNAs in cardiac matrix
Cardiac matrix is implicated in conferring biochemical stability of
growth factors, facilitating signal transduction and inducing apopto-
sis [23]. Since MMPs degrade cardiac matrix, they also disrupt the
endothelial–myocyte coupling, signaling cascade and regulatorymachin-
ery necessary for maintaining normal function [9]. MicroRNAs (miRNAs)
are small (20 23 nucleotide long), non-coding RNAs that regulate gene
expression either by mRNA degradation or translational repression
[45,46]. Nearly 2000miRNAs have been reported in humans. MicroRNAs
play a pivotal role in the regulation of cardiovascular diseases [6,47].
MMPs also alter the expression of miRNAs. The ﬁrst report of regulation
of miRNAs by MMPs was documented in MMP-9KO hearts [7]. This
study revealed several key miRNAs that are downregulated in the failing
heart, are up regulated in theMMP-9KO hearts [7]. However, the mecha-
nism of miRNA regulation by MMPs is still not clear. Nevertheless, this
ﬁnding opens a new avenue to explore the complex regulatory network
betweenMMPs andmiRNAs and dissect themechanismof cardiacmatrix
remodeling in pathological conditions.
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ECM is the key component of themyocardiumwhich not onlymain-
tains the structural integrity and plasticity of the heart but also provides
the micro-environment for signaling cascade required for cardiac ho-
meostasis [48]. Collagen provides stiffness to ECM and is involved in
structural remodeling leading to heart failure [8,9,48–50]. Collagen is a
substrate for bothMMP-2 andMMP-9 [10].MMP-9 is found to be robust
and degraded ECM in a failing heart [51–53]. Targeted deletion ofMMP-9
mitigated ﬁbrosis in diabetic hearts [8]. During the remodeling process,
though both collagen and elastin are resynthesized as a compensatory
mechanism, collagen turnover is faster thanelastin and contributes to car-
diac ﬁbrosis. The cardiac ﬁbrosis impairs endothelium cardiomyocyte
(EC) coupling leading to ventricular dysfunction [9]. The role of MMP-9
on contractility of the heart was elucidated by an ex-vivo experiment, in
which treatment withMMP-9 decreases rate of contraction and relaxa-
tion (±dL/dt) of cardiomyocytes and inhibition of MMP-9 by tissue in-
hibitor of metalloproteinase-4 (TIMP4) ameliorated impaired
contractility [7]. The targeted deletion of MMP-9 also improved con-
tractility of cardiomyocytes at in vivo studies [7].
Micro RNA-133 is attenuated in heart failure. Inhibition of miR-133
induced cardiac hypertrophy [54] while transgenic expression of
miR-133 attenuated cardiac ﬁbrosis in trans-aortic constriction model
of heart failure [55]. Interestingly, targeted deletion of MMP-9 up-
regulated the expression of miR-133 in a failing heart [7]. Recently, it
was reported that abrogation of miR-133 induces DNA methyl
transferases (DNMTs) and over expression of miR-133 inhibits
DNMTs in cardiomyocytes [56]. Surprisingly, up-regulation of miR-133
downregulates hyperglycemia mediated induction of DNMTs (DNMT-1)
suggesting a crucial role ofmiR-133 in epigeneticmodiﬁcation in diabetic
hearts [56]. Although ablation ofMMP-9 inducesmiR-133, the underlying
mechanism is unclear. The plausible mechanism of MMP-9 mediated
amelioration of heart failure could be that the deletion of MMP-9 gene
provides a favorable cardiac matrix micro-environment required for in-
creased transcription of speciﬁc miRNAs thatmitigates cardiac dysfunc-
tion. Further understanding of cross-talk between ECM, MMPs and
miRNAs will open a new avenue to elucidate the complex regulatory
network in the heart that can be exploited for therapeutic endeavor.5. Elasticity of cardiac matrix and stem cell survival
and differentiation
Stem cells are recognized by three salient properties, (i) self-renewal,
(ii) pluripotent, and (iii) clonogenic [57]. The human heart is a self-
renewing organ [3] because of its endogenous cardiac stem cells and
self-renewal is dependent on the elasticity of the surrounding ma-
trix [1,2]. The ECM elasticity determines stem cell lineage speciﬁca-
tion, expansion and differentiation [1,8]. In the heart, ECM exhibitsFig. 2. Activation of MMP-9 increases ECM turn over, attenuates miRNAs, induces cardiac stemall the mechanical properties and provides a frame work required
for differentiation of cardiac stem cells [58]. The contractility of
cardiomyocytes also depends on the elasticity of matrix [2]. It is doc-
umented that embryonic cardiomyocytes beat best on a matrix with
heart like elasticity [2]. As MMP-9 deletion contributes to the elastic-
ity of ECM and up-regulates several miRNAs involved in stem cell dif-
ferentiation, we determined the role of MMP-9 in the survival and
differentiation of cardiac stem cells [8]. The comparative analysis of
c-kit (a stem cell marker) and troponin I (cardiomyocytes marker)
in theWT, diabetic Ins2+/− Akita and Ins2+/−/MMP−9−/− (diabetic
mice without MMP-9 gene) revealed that MMP-9 deletion enhances
stem cell survival and differentiation to cardiomyocytes in the heart [8].
It points to a complex interaction amongst MMPs (at least MMP-9),
ECM elasticity and miRNAs that determines the cardiac stem cell
survival and differentiation. ECM might be crucial for regulating
stem cell differentiation signaling in autocrine and paracrine fashion
for regenerating the myocardium that is pivotal in stem cell therapy
(Fig. 2).6. MMPs, angiogenesis, cardiovascular remodeling and repair
Aberrant remodeling in the myocardial ECM results in heart failure.
MMPs play a pivotal role in regulation of angiogenesis by altering the
balance between angiogenic and anti-angiogenic factors [16,59,60].
Brooks and colleagues reported that an angiogenic stimulus induces vas-
cular remodeling and deﬁnes the role of MMP-2 and integrin (αvβ3)
[61,62]. During hypertrophic remodeling and angiogenesis, MMP-2 is
constitutively expressed [16,49]. Alternatively, MMP-9 is expressed in
the failing heart and induces the expression of anti-angiogenic factors—
endostatin and angiostatin [16,50,63]. Previous reports demonstrated
that the therapeutic angiogenesis using growth promoting factors can in-
crease blood supply to the ischemic myocardium [64–66]. Studies in car-
diac speciﬁc inducible protein kinase B (AKT1) transgenic mice show
decreased angiogenesis during pathological remodeling and suggested
that both heart size and cardiac function are angiogenesis dependent. Ad-
ditionally, the disruption of coordinated cardiac hypertrophy and angio-
genesis plays a crucial role in the pathogenesis of heart failure [67].
Although role ofMMPs in acute coronary syndrome (ACS) is documented
[23,24], the inhibition of vascular versus cardiacMMP is counter intuitive.
The comparative analyses of angiostatin, endostatin and coronary collat-
eral formation in myocardial tissue harvested from diabetic and non-
diabetic coronary artery disease (CAD) patients revealed that angiostatin
and endostatin are induced in diabetic CAD patients compared with non-
diabetic patients and negatively correlateswith coronary collateralization
[63]. Although MMPs are integral regulators of angiogenesis and anti-
angiogenesis, whether all MMPs have similar or differential function is
nebulous. MMP-2 andMMP-9 are mostly studiedMMPs in angiogenesis;
however contrasting roles have been reported. We and several otherscell apoptosis and inhibits their differentiation leading to pathological cardiac remodeling.
Fig. 3.Mechanism of pressure overload (ascending aortic banding)mediated compensatory
cardiac hypertrophy to de-compensatory heart failure. During early stages of aortic banding,
angiogenesis is increased due to up-regulation ofMMP-2, vascular endothelial growth factor
(VEGF) and inhibition of MMP-9. However, sustained overload results in de-compensatory
heart failure due to anti-angiogenesis, where expression of MMP-9 supersedes that of
MMP-2 and promotes release of anti-angiogenic factors such as angiostatin, endostatin
and parstatin. MMP-9 also stimulate endothelial mesenchymal transition (EndMT) leading
to ﬁbrosis and end stage heart failure.
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the heart [16,63,68]. The role of MMP-9 as anti-angiogenic factor is also
supported by the ﬁnding that abrogation of MMP-9 attenuates cardiac
hypertrophy and collagen accumulation in the heart after myocardial in-
farction [69]. It is documented that endothelial mesenchymal transition
(EndMT) similar to that of epithelial mesenchymal transition (EMT)
plays an important role in synthesizing new ﬁbroblasts resulting in
increased deposition of ﬁbrosis in endocardium and microvascular
endothelium [70–72]. However, ablation of MMP-9 gene inhibits EMT
[71,73]. These ﬁndings points to the role of MMP-9 as inducer of EndMT
in cardiac and vascular endothelium that promotes cardiac ﬁbrosis
along with increased expression of anti-angiogenic factors such asFig. 4. The effect of different vascular endothelial growth factors (VEGF) following their binding
genesis through Flt-1 and Flk-1/KDR pathway, whereas VEGF3 enhances lymphangiogenesis thangiostatin and endostatin in an experimental ascending aortic banding
model (Fig. 3).
Imbalance of angiogenesis and anti-angiogenesis could be one of the
major pathogenic mechanisms during cardiac injury such as pressure
overload, ischemia and infarction. Restoration of angiogenesis may po-
tentiate myocardial recovery from an insult or injury. We and others
have reported that therapeutic doses of hydrogen sulﬁde (H2S) promote
angiogenesis and have cardio protective role in pressure overloadmodels
[68,74,75]. Since homocysteine is a precursor for H2S, the treatment with
H2S can mitigate hyperhomocysteinemia mediated cardiac toxicity. Al-
though angiogenic therapy for the cardiac repair is promising, successful
clinical data is still missing and targeted induction of angiogenesis in the
localized area of heart could be a viable approach for cardiac repair. Em-
pirical studies revealed that administration of self-assembling peptide
nanoﬁber combined with VEGF in the post myocardial infarction heart
stabilizedVEGF locally formore than 14 days and improved angiogenesis,
arteriogenesis and cardiac performance [76]. This study upholds the car-
diac angiogenesis therapy for future clinical trials. However, understand-
ing the types of VEGF and their functions in relation to cardiac repair is
crucial as different VEGFs are involved in vasculogenesis, angiogenesis
and lymphangiogenesis (Fig. 4).7. Exploiting cardiac matrix for future therapy
Cardiac matrix contains MMPs, TIMPs, miRNAs, DNMTs, cardiac stem
cells, angiogenic and anti-angiogenic factors, signaling molecules in-
volved in autophagy, apoptosis, epigenetic modiﬁcations, ﬁbrosis and
hypertrophy. The unique interactions of these factors in the favorable car-
diacmatrixmilieumaintain synchronized beating of cardiomyocytes and
contractility of the heart. However, differential expressionof even a single
molecule disrupts the sophisticated regulatory network by altering the
matrix milieu that leads to pathological remodeling. For example, inhibi-
tion of only miR-133 causes cardiac hypertrophy [54]. Similarly, ablation
ofMMP-9 reduces cardiacﬁbrosis [8]. In the diabetic heart,miR-133 is at-
tenuated that induces DNAmethylation [56] but MMP-9 is up-regulated
that contributes to cardiac ﬁbrosis [9]. Attenuation of miR-133 is also re-
sponsible for cardiac ﬁbrosis [55]. Therefore, the interactions of miR-133,
MMP-9, epigenetic modiﬁcations and cardiac ﬁbrosis are somehowto corresponding receptors (VEGFR). VEGF1 and 2 up-regulates vasculogenesis and angio-
rough Flt-4 pathway.
Fig. 5. The unique cross-talk amongst MMP-9/TIMP4, miRNA, epigenetic modiﬁcation, ﬁ-
brosis, hypertrophy, cardiac stem cell proliferation and differentiation, growth factors, au-
tophagy and apoptosis is maintained in the cardiac matrix. The interactions of these
molecules alter in pathological remodeling due to change in matrix milieu. Dissecting
the causative factor(s) and their interactions will provide a clue to for future therapy.
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and MMP-9 regulates stem cell survival [8] and miRNA levels [7]. There-
fore, CSC survival, differentiation and function depend on interactions of
miRNAs and MMP-9. As elucidated above, there are empirical evidences
suggesting the role of MMP-9 and MMP-2 in angiogenesis, which is a
promising area for therapy of cardiovascular diseases. The interactions
of these factors constitute the dynamic cardiac matrix. There is very little
known about how the dynamic cardiacmatrix behaves duringmyocardi-
al regeneration, pathological cardiac remodeling and compensatory and
de-compensatory stages of heart failure. The detailed insights of signaling
cascade of apoptosis, autophagy, epigenetic modiﬁcations and angiogen-
esis by cardiacmatrix in the failing heart and their regulation bymiRNAs,
MMPs and TIMPs will provide a clue for future therapy for heart failure
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